• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RCE
Click for more information
0.00% 66.0¢

RECCE PHARMACEUTICALS LTD - News & Media

Market Cap $134.6M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce... An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.More

Corporate Spotlight

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight arrow Created with Sketch.

RCE UPDATE HIGHLIGHTS KEY DEVELOPMENTS FOR UPSIDE

Articles & Videos

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in Phase I/II trials following safety board approval.

6 days ago

Recce weighs in on Q1 2024 as cash increases 100%

Recce Pharmaceuticals, developing a new body of anti-infectives for global markets, weighs in on the last three months.

22 Apr 2024 11:11 (AEST)

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.

16 Apr 2024 12:54 (AEST)

Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel

Recce Pharmaceuticals published a business update highlighting two key developments with the potential to deliver share price upside.

08 Apr 2024 13:56 (AEST)

Recce Pharmaceuticals inks new patent for flagship drug in Israel

Recce Pharmaceuticals (ASX:RCE) has successfully obtained a patent for its flagship anti-infective drug R327 in Israel.

03 Apr 2024 10:41 (AEDT)

Recce Pharmaceuticals secures Trademark Registration in Canada

Recce Pharmaceuticals secures Trademark Registration in Canada for its antibiotics.

21 Mar 2024 14:11 (AEDT)

Recce reaches testing milestone for UTI, Uroseptis antibiotic

Recce Pharmaceuticals Limited (ASX: RCE) has completed tests involving a four-person cohort for its RECCE 327 (R237) synthetic antibiotic.

15 Mar 2024 11:23 (AEDT)

Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial

Recce Pharmaceuticals (ASX: RCE) has announced the successful dosing of the latest group of human participants with RECCE 327 (R327).

12 Mar 2024 13:32 (AEDT)

Recce Pharmaceuticals secures AUD$11.18M from Endpoints Capital

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) has announced the receipt of an AUD$11,178,965 R&D Advance from Endpoints Capital.

08 Mar 2024 12:16 (AEDT)

Recce Pharmaceuticals leads the way in collaborative Anti-Infective research

Recce Pharmaceuticals (ASX:RCE) has announced the ongoing initiatives within its Anti-Infective Research (AIR) Unit situated at the Murdoch Children’s Research Institute (MCRI) in Victoria.

27 Feb 2024 12:07 (AEDT)



(20min delay)
Last
66.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $134.6M
Open High Low Value Volume
66.0¢ 66.0¢ 63.5¢ $31.87K 49.28K

Buyers (Bids)

No. Vol. Price($)
3 15997 65.0¢
 

Sellers (Offers)

Price($) Vol. No.
66.0¢ 40297 3
View Market Depth
Last trade - 16.10pm 01/05/2024 (20 minute delay) ?
Last
66.0¢ 		  Change
0.000 ( 1.54 %)
Open High Low Volume
65.5¢ 66.0¢ 64.5¢ 17052
Last updated 15.59pm 01/05/2024 ?
RCE (ASX) Chart

Top Stories

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and potential of BlinkLab's (ASX:BB1) AI-driven smartphone app, designed to screen for autism and ADHD.
Carnarvon revs up for revised Dorado Development The Dorado discovery appears on again, with Carnarvon Energy announcing the JV completing a revision of the project’s design to optimise capital costs and accelerate FID by the end of 2024.
Recharged Prospects: 'Watts' on the horizon for copper & lithium The conversation goes much deeper that this title suggests - it explores everything from projections on aluminium & manganese, to what a Donald Trump government could mean for commodities markets.
Lithium Universe ends the quarter charged up for Quebec Refinery roll-out Lithium Universe has closed off the March quarter with a new Chief Financial Officer and strategically located land anchored for its lithium refinery in Quebec, Canada.
Provident Aurum's off-market bid sends Sihayo shares soaring Small-cap mineral and gold explorer, Sihayo Gold (ASX:SIH) shares have soared, on news that the company has received intentions from Provident Aurum Pte to make an off-market takeover offer to acquire all shares of Sihayo Gold.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.